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Osteoporosis is a common disease characterized by a systemic impairment of bone mass
and microarchitecture that results in fragility fractures. Severe bone loss due to
osteoporosis triggers pathological fractures and consequently decreases the daily life
activity and quality of life. Therefore, prevention of osteoporosis has become an important
issue to be addressed. We have reported that the fungal secondary metabolite (+)-terrein
(TER), a natural compound derived from Aspergillus terreus, has shown receptor activator
of nuclear factor-κB ligand (RANKL)–induced osteoclast differentiation by suppressing
nuclear factor of activated T-cell 1 (NFATc1) expression, a master regulator of
osteoclastogenesis. TER has been shown to possess extensive biological and
pharmacological benefits; however, its effects on bone metabolism remain unclear. In
this study, we investigated the effects of TER on the femoral bone metabolism using a
mouse-ovariectomized osteoporosis model (OVX mice) and then on RANKL signal
transduction using mouse bone marrow macrophages (mBMMs). In vivo administration
of TER significantly improved bone density, bone mass, and trabecular number in OVX
mice (p < 0.01). In addition, TER suppressed TRAP and cathepsin-K expression in the
tissue sections of OVX mice (p < 0.01). In an in vitro study, TER suppressed RANKL-
induced phosphorylation of PKCα/βII, which is involved in the expression of NFATc1 (p <
0.05). The PKC inhibitor, GF109203X, also inhibited RANKL-induced osteoclastogenesis
in mBMMs as well as TER. In addition, TER suppressed the expression of
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osteoclastogenesis-related genes, such as Ocstamp, Dcstamp, Calcr, Atp6v0d2, Oscar,
and Itgb3 (p < 0.01). These results provide promising evidence for the potential therapeutic
application of TER as a novel treatment compound against osteoporosis.
Keywords: (+)-terrein, ovariectomy, osteoporosis, RANKL, PKC
INTRODUCTION
At present, more than 15 million people have osteoporosis, which
is a serious problem in Japan, where the population is extremely
aged (Hagino et al., 2021). In the United States, there were more
than 2 million osteoporosis-related fractures in 2005, with
associated costs of approximately $ 17 billion. By 2023, the
annual number of fractures will exceed 3 million, and the U.S.
healthcare system is projected to cost $ 25 billion (Burge et al.,
2007). Osteoporosis is caused by a deficiency of female hormone
estrogen, which breaks bone homeostasis between osteoclasts and
osteoblasts. Severe bone loss due to osteoporosis triggers
pathological fractures and, consequently, decreases daily life
activity and the quality of life. Therefore, the prevention of
osteoporosis is one of the most urgent issues in Japan (Tilman
et al., 2011; Katrin, 2019).
Currently, bisphosphonates (BPs) are mainly used in the
treatment of osteoporosis (Shibahara et al., 2018). However,
medicine-induced osteonecrosis of the jaw (MRONJ), which
occurs after invasive dental procedures, such as tooth
extraction, scaling, and root planning, has become a major
problem in the treatment of osteoporosis, including BP
treatment (Yoneda et al., 2017). The incidence of MRONJ in
Japan is 0.85 per 100,000 people per year (Yoneda et al., 2017).
According to a nationwide survey by the Japanese Society of Oral
and Maxillofacial Surgery, it is estimated to be approximately
0.01–0.02% (Yoneda et al., 2010). In Japan, the number of
remaining teeth in the elderly continues to increase as a result
of the 8,020 movement (Nasu and Nakamura, 2016). Therefore,
since MRONJ significantly decreases the quality of life of patients,
it is desirable to develop new osteoporosis drugs without serious
side effects.
Our research group has identified (+)-terrein (TER, Figure 1)
as a naturally occurring compound with a different mechanism of
action from that of molecularly targeted drugs, which is expected
to have an anti-inflammatory effect by inhibiting interleukin (IL)-
6 (Mandai et al., 2014). TER is a small molecule with a molecular
weight of 154.16 kDa isolated from Aspergillus terreus as a
secondary metabolite (Raistrick and Smith, 1935). TER has
been reported to have various biological effects, such as
inhibiting biofilm formation (Kim et al., 2018), angiogenin
secretion in prostate cancer cells (Arakawa et al., 2008), and
pulp inflammation (Lee et al., 2008). In addition, our group has
established a route for the organic synthesis of TER (Mandai et al.,
2014). Furthermore, this synthesized TER inhibits IL-6–induced
vascular endothelial growth factor (VEGF) secretion in human
gingival fibroblasts (Mandai et al., 2014). In addition, synthetic
TER suppressed IL-6–induced macrophage colony-stimulating
factor (M-CSF) secretion by inhibiting Janus-activated kinase
(JAK)-1 phosphorylation (Yamamoto et al., 2018). We have also
reported that TER has an inhibitory effect on RANKL or tumor
necrosis factor (TNF)-α–induced osteoclastogenesis by
suppressing the expression of nuclear factor of activated T-cell
c1 (NFATc1), a master regulator of osteoclast differentiation in
mouse bone marrow macrophages (mBMMs) (Nakagawa et al.,
2020). In addition, we also showed that TER did not suppress
RANKL-induced phosphorylation of NF-κB and MAPKs (ERK1/
2 and p38), which are related to NFATc1 expression, meaning
which it is still unknown about the effects of TER on RANKL
signaling (Nakagawa et al., 2020). Based on these in vitro findings,
we hypothesized that TER could suppress bone resorption in the
femur if its anti-inflammatory and anti-osteoclastogenic effects
were effectively exerted in the bones. However, the in vivo effect
of TER on bone destruction remains unknown. In addition, to the
best of our knowledge, there have been no studies on whether
TER also acts on osteoblasts and whether it has an effect on bone
homeostasis.
In this study, we evaluated the effect of TER on bone
homeostasis in vivo using a mouse ovariectomy model of
osteoporosis (OVX mice). We also assessed the effects of TER
on the signaling pathways of RANKL-induced osteoclast
differentiation using mBMMs in vitro, especially focused on
protein kinase-C cascade which is also related to NFATc1
expression (Shin et al., 2014). PKC family members
phosphorylate a wide variety of protein targets and are known
to be involved in diverse cellular signaling pathways. In RANKL-
induced osteoclast formation, PKC β functions, but not PKCδ,
occur through glycogen synthase kinase-3β (GSK-3β)–NFATc1
axis (Shin et al., 2014). We also assessed the effects of TER on
osteoblast differentiation using MC3T3-E1 cells in vitro. Our
FIGURE 1 | Chemical structure of (+)-terrein. Me: methyl.
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results suggest that host modulation using TER could be a novel




TER was synthesized from dimethyl L-tartrate. All spectra,
including 1H and 13C nuclear magnetic resonance (NMR)
spectra, infrared (IR) spectra, and specific rotation of the
synthetic TER, were similar to those of natural TER and those
that were previously described (Mandai et al., 2014). The
following were used: human soluble RANKL (Wako,
Hiroshima, Japan), human M-CSF (Leucoprol, Kyowa Hakko
Kogyo, Japan), zoledronic acid (ZOL: Tokyo Chemical Industry,
Japan), rabbit anti-total PKCα, rabbit anti–phospho-PKCα/βII
and PKCδ monoclonal antibodies (Cell Signaling Technology
Danvers, MA, United States), mouse anti–β-actin monoclonal
antibody (Sigma-Aldrich, St. Louis, MO, United States), and the
PKC inhibitor GF109203X (Bisindolylmaleimide I, Selleckchem,
Japan).
The Ovariectomized Mice Model
Female C57BL/6J mice were obtained from Japan CLEA
(Japan) and allowed to acclimatize for 1 week. At 8 weeks of
age, mice were randomly divided into four groups (n  6–7 per
group): 1) Sham, 2) OVX, 3) OVX + TER (10–30 mg/kg, two
times a week), and 4) OVX + ZOL (0.1 mg/kg, two times a
week). A fake operation was performed in the Sham group as a
control, and the other three groups underwent bilateral OVX
under anesthesia with sodium pentobarbital (60 mg/kg) via
intraperitoneal injection (Thompson et al., 1995; Xiao et al.,
2018; Xu et al., 2018). The Sham and OVX groups received
equal doses of phosphate-buffered saline (PBS) as controls, the
OVX + TER group was given an intraperitoneal injection of
TER at the indicated concentrations, and the OVX + ZOL
group received an intraperitoneal injection of ZOL at the
indicated concentrations after surgery. After 8 weeks, all
mice were euthanized via cardiac stick exsanguination.
Serum samples were prepared and stored at −80°C for the
measurement of tumor necrosis factor (TNF)-α, IL-1β, IL-6,
and M-CSF. The femurs of the mice were collected. This
animal experiment was performed in accordance with the
Guidelines for Proper Conduct of Animal Experiments of
the Science Councils of Japan and approved by the Animal
Research Control Committee of Okayama University
(approval no: OKU-2018756), and the mice were kept
under SPF conditions (Figure 2).
Image Analysis Using Micro-Computed
Tomography
To observe the femur bone resorption, 4-μm-thick slices from the
mice from each group were photographed using an animal micro-
CT imaging device (Skyscan: Bruker, Kontich, Belgium), and these
images were reconstructed using the accompanying software
(Reconstruction software, NRecon: Bruker) and analyzed using
the image processing software (Analyze software, CT-Analyzer:
Bruker). We measured the indicators of bone mineral density
(BMD, mg/cm3), bone volume/trabecular volume (BV/TV, %),
trabecular number (Tb.N, 1/μm), and trabecular separation
(Tb.Sp, μm).
Histological Analysis
The femur samples were fixed in a 4% paraformaldehyde solution
(pH 7.4; Wako Pure Chemicals, Osaka, Japan) for 1 day. The
blocks were immersed in disodium ethylenediaminetetraacetic
acid (10% EDTA 2Na solution, pH 7.0, Muto Chemical Co., Ltd.,
Tokyo, Japan) for 10 days for demineralization, and were
dehydrated using an ethanol series. Paraffin-embedded blocks
were sliced into 4-μm-thick sections. Subsequently,
histopathological analysis was performed using the following
staining methods.
Hematoxylin-Eosin Staining
The prepared paraffin sections were subjected to HE staining,
according to the normal method, and then encapsulated using a
cover glass and Mount-Quick (Daido Sangyo Co., Ltd., Tokyo,
Japan). Histological images were then observed under an optical
microscope (BX-50; Olympus, Osaka, Japan).
Tartrate-Resistant Acid Phosphatase Staining
The prepared paraffin sections were stained with a TRAP staining
solution (Cosmo Bio Co., Ltd., Tokyo, Japan) according to the
conventional method, and then encapsulated with a cover glass
and Mount-Quick Aqueous medium. Histological images were
then observed under an optical microscope. The number of
TRAP-positive cells that existed within 3 mm just below the
growth plate and that had at least three nuclei were counted
as osteoclasts. The number of osteoclasts was measured in nine
sections from three mice in each group, and three sections from
each mouse were selected at random.
Immunohistochemical Staining
The prepared paraffin sections were deparaffinized, rehydrated,
and stained using the avidin–biotin peroxidase system and the
Vectastain Elite ABC rat kit (Vector Laboratories, Burlingame,
CA, United States). Tissue sections were immersed in a 0.3%
hydrogen peroxide in methanol solution for 30 min at room
temperature to remove the endogenous peroxidase activity and
treated with trypsin (Thermo Fisher Scientific) for 15 min for
antigen activation. After blocking with normal rabbit serum for
15 min, the primary antibodies were added and reacted overnight
at 4°C. For the primary antibodies, anti–cathepsin-K and anti-
alkaline phosphatase antibodies (Abcam, Cambridge, MA,
United States), which are specific marker proteins of
osteoclasts and osteoblasts, were diluted (100-fold) in PBS;
they were washed in PBS, and rabbit anti-rat biotin-labeled
secondary antibodies were added by diluting (200-fold) in PBS
and were left to react for 30 min at 25°C. The
avidin–biotin–labeled enzyme complex was added and reacted
for 30 min, followed by the addition of 0.01% 3,3′-
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diaminobenzidine (DAB; Nacalai Tesque Co., Ltd., Kyoto, Japan)
for coloration. Finally, cell nuclei were contrast-stained with
Mayer’s hematoxylin (Wako), observed after enclosure using a
cover glass and Mount-Quick, and the positive cells were
counted.
Enzyme-Linked Immunosorbent Assay
Fresh blood was collected from the hearts of mice in each group.
The serumwas collected via centrifugation at 10,000 × g at 4°C for
15 min. The secretion of serum inflammatory cytokines (IL-1β,
IL-6, TNF-α, and M-CSF) was measured using ELISA MAX
Deluxe (BioLegend, San Diego, CA, United States) and
Quantikine ELISA Kit (R&D systems, Minneapolis, MN,
United States), following the manufacturer’s instructions. The
absorbance at 450 nm was measured using a microplate reader
(SH-1000 Lab; Corona Electric Co., Hitachinaka, Japan). All tests
were performed in two wells per individual. The serum
concentrations of IL-1β, IL-6, TNF-α, and M-CSF were
quantified, and the concentrations were set to 0 if the results
were below the detection limit.
Cell Culture
Mouse Bone Marrow Macrophages
Five-week-old male C57BL6/J mice were obtained from Japan
CLEA (Japan). Bone marrow cells were collected from the tibiae
and femur, and were cultured in M-CSF (50 ng/ml) for 3 days in
culture dishes containing DMEM (Wako) supplemented with
10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA,
United States). After 3 days, floating cells were removed by
rinsing with phosphate-buffered saline (PBS), and the attached
cells were used as mBMMs (Horibe et al., 2013; Tevlin et al.,
2014). Attached mBMMs were sprayed with PBS to remove the
culture dish mechanically to use for the following in vitro
experiments. This animal experiment was performed in
accordance with the Guidelines for Proper Conduct of Animal
Experiments of the Science Councils of Japan and approved by
the Animal Research Control Committee of Okayama University
(approval no. OKU-2016277).
Mouse Cranial Crown–Derived Cells (MC3T3-E1 Cells)
MC3T3-E1 cells (ATCC, Manassas, VA, United States) were used
as pre-osteoblasts. MC3T3-E1 cells were cultured for 3 days in
culture dishes containing DMEM (Wako) supplemented with
10% FBS (Invitrogen) and antibiotics (0.2 mg/ml gentamicin)
(Gibco). Osteogenic differentiation was investigated by
supplementing media with 50 mg/L ascorbic acid, 10 μM
hydrocortisone, and 10 mM β-glycerophosphate (Takara Bio,
Shiga, Japan) (Aaron et al., 2010).
Western Blotting
mBMMs (1.0 × 105 cells/well) were harvested from a 12-well plate
and treated with RANKL (100 ng/ml) and M-CSF (100 ng/ml) in
the presence and absence of TER (10 μM) for 10–30 min (to
detect PKCα, phospho-PKCα/βII, and phospho-PKCδ
expression). After each time course, cells were lysed rapidly by
adding ice-cold cell lysis buffer containing 50 mM NaCl, 10 mM
Tris-HCl (pH 7.2), 1% Nonidet P-40, 5 mM EDTA-Na, 1 mM
sodium ortho vanadate, 1% sodium dodecyl sulfate (SDS), and a
protease inhibitor cocktail (Sigma-Aldrich) for 10 min, according
to a previously described method (Omori et al., 2004). Protein
concentration was determined using a Bradford assay by using
bovine serum albumin (BSA, Sigma-Aldrich) as the standard
(Bradford, 1976). The lysates (30 μg) were mixed with SDS
sample buffer (1% [w/v] SDS, 45 mM Tris-HCl [pH 6.8], 15%
[v/v] glycerol, 144 mM 2-mercaptoethanol, and 0.002%
bromophenol blue), and samples were boiled for 5 min. The
samples were separated using SDS-polyacrylamide gel
electrophoresis (PAGE) on a 7.5% or 12% polyacrylamide slab
gel and transferred onto polyvinylidene difluoride membranes.
These membranes were blocked with 5% skim milk in Tris-
buffered saline with Tween 20® (TBST; 20 mMTris-HCl (pH 7.6)
containing 150 mM NaCl and 0.1% (v/v) Tween 20®) for 1 h and
incubated with anti–phospho-PKCα/βII (1:1,000) and anti-total
PKCα (1:1,000) overnight at 4°C. The membranes were incubated
with secondary antibodies (goat anti-rabbit immunoglobulin G
(IgG)–horseradish peroxidase (HRP) conjugate, 1:2,000 dilution;
GE Healthcare, Chicago, IL, United States) for 1 h. HRP activity
FIGURE 2 | Schedule of the animal experiments. Eight-week-old C57BL/6 mice underwent ovariectomy and were randomly divided into four groups. Two weeks
after ovariectomy, the mice were treated with (1) TER (10 mg/kg), (2) TER (30 mg/kg), and (3) PBS (200 μL) as a negative control, and (4) zoledronic acid (0.1 mg/kg) as a
positive control; human dose was converted to mouse weight. Intraperitoneal injections were administered twice a week. The Sham group was sham-operated and
administered PBS. Eight weeks after ovariectomy, the mice were sacrificed, and the femur bones and serum were collected.
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was visualized by incubating the membranes and using an
electrochemiluminescence (ECL) detection system
(SuperSigna® West Dura Extended Duration Substrate,
Thermo Fisher Scientific), followed by autoradiography. At the
end of these experiments, the immunodetection system and the
bound antibody were removed from the blots by incubating the
membranes with re-probing buffer (Restore™ Western Blot
Stripping Buffer, Thermo Fisher Scientific). The blots were
then stained with anti–β-actin antibody (1:2,000 dilution) to
confirm that equal amounts of protein were present in each
lane of the gel.
Real-Time Polymerase Chain Reaction
mBMMs (1.0 × 105 cells/well) were harvested from a 12-well plate
and treated with RANKL and M-CSF (100 ng/ml each) in the
presence and absence of TER (10 μM) for 2 days. Total
ribonucleic acid (RNA) was then isolated using the RNeasy®
Mini Kit (Qiagen, Hilden, Germany), followed by
deoxyribonucleic acid (DNA) removal using an RNase-free
DNase Kit (Qiagen). A total of 1 μg of high-quality total RNA
was then reverse-transcribed using the SuperScript® III First-
Strand Synthesis System (Thermo Fisher Scientific, Waltham,
MA, United States). Amplification reactions were performed
using SYBR® Green PCR Master Mix (Thermo Fisher
Scientific). Up to 1 ng of complementary DNA was then
amplified using specific primers. The reactions were performed
using a 7,300 Real-Time PCR System (Thermo Fisher Scientific).
The ratios of messenger RNA levels to control values were
calculated using the ΔCt method (2−ΔΔCt). All data were
normalized to the housekeeping control gene, β-actin. The
PCR conditions used were as follows: 10 min at 95°C, followed
by 40 cycles of 15 s at 95°C, and 60 s at 60°C. The primers used
were as follows: 5′-TGGGCCTCCATATGACCTCGAGTAG-3′
(forward) and 5′-TCAAAGGCTTGTAAATTGGAGGAGT-3′
(reverse) for osteoclast stimulatory transmembrane protein
(Ocstamp), 5′-CTAGCTGGCTGGACTTCATCC-3′ (forward)
FIGURE 3 | Synthetic TER suppressed ovariectomy-induced bone loss. (A) The 3D model of the femur was created within 3 mm just below the growth plate (the
preferred site of femoral fracture). (B) Bone mineral density (BMD, mg/cm3), bone volume/trabecular volume (BV/TV, %), trabecular number (Tb.N, 1/μm), and trabecular
separation (Tb.Sp, μm) were analyzed in each group (n  6–7, **p < 0.01, *p < 0.05, ANOVA/Tukey–Kramer test). Sham: PBS-treated non-osteoporosis mice; OVX:
PBS-treated osteoporosis mice; OVX + TER: TER-treated osteoporosis mice.
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FIGURE 4 | Synthetic TER suppressed osteoclast differentiation. Representative histological images of (A) HE-stained, (B) TRAP-stained (osteoclast), and (C)
anti–cathepsin-K antibody–stained cells in each group are shown. The enlarged image of the area enclosed in the black line frame of the HE-stained image is shown in the
lower row. Numbers next to the images indicate the magnification; scale bar: 500 µm (at a ×40 magnification) and 200 µm (at a ×200 magnification). (D) The number of
osteoclasts on the femur bone was measured (n  3, mean ± SD, **p < 0.01, ANOVA/Tukey–Kramer test) by defining the osteoclasts as cells that were TRAP
positive and which had more than three nuclei. The number of positive cathepsin-K–expressing cells on the femur was measured (n  3–4, mean ± SD, *p < 0.05,
ANOVA/Tukey–Kramer test) by defining positive cells as those with darker cathepsin-K staining around the cell nucleus. Error bars: SD; dots: measured values; PBS:
phosphate-buffered saline; Sham: PBS-treated non-osteoporosis mouse; OVX: PBS-treated osteoporosis mouse; OVX + TER: TER-treated osteoporosis mouse.
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and 5′-TCATGCTGTCTAGGAGACCTC-3′ (reverse) for
dendritic cell–specific transmembrane protein (Dcstamp), 5′-
TGCAGACAACTCTTGGTTGG-3′ (forward) and 5′-TCG
GTTTCTTCTCCTCTGGA-3′ (reverse) for calcitonin receptor
(Calcr), 5′-TCAGATCTCTTCAAGGCTGTGCTG-3′ (forward)
and 5′-GTGCCAAATGAGTTCAGAGTGATG-3′ (reverse) for
v-type protein ATPase subunit d2 (Atp6v0d2), 5′-CTGCTGGTA
ACGGATCAGCTCCCCAGA-3′ (forward) and 5′-CCAAGG
AGCCAGAACCTTCGAAACT-3′ (reverse) for osteoclast-
associated receptor (Oscar), 5′-ATGCCAGCGACAAGAGGT
TC-3′ (forward) and 5′-TGGTTTCCAGCCAGCACATAC-3′
(reverse) for Trap (Acp5), 5′- TGACCACTGCCTTCCAAT
ACG-3′ (forward) and 5′-TGCATTTAGCTGCCTTTGCC-3′
(reverse) for cathepsin-K, 5′-TGTGTGCCTGGTGCTCAGA-3′
(forward) and 5′-AGCAGGTTCTCCTTCAGGTTACA-3′
(reverse) for integrin β3 (Itgb3), 5′-CCAGTCAAGAGCATC
AGCAA-3′ (forward) and 5′-AAGTAGTGCAGCCCGGAG
TA-3′ (reverse) for Proto-oncogene c-fos (c-fos), and 5′-TAG
CGGAACCGCTCATTGCC-3′ (forward) and 5′-TTCACCCAC
ACTGTGCCC-3′ (reverse) for β-actin (Kwak et al., 2010; Choi et
al., 2012; Lee et al., 2012; Ma et al., 2014; Shimada-Sugawara et al.,
2015; Nakagawa et al., 2020).
Alizarin Red Staining and Alkaline
Phosphatase Staining
MC3T3-E1 cells (1.0 × 105 cells/well) were cultured onto 48-well
plates, and treated withDMEM (Wako) supplemented with 10% FBS
(Invitrogen), antibiotics (0.2 mg/ml gentamicin) (Gibco), 50mg/L
ascorbic acid, hydrocortisone, and 10mM β-glycerophosphate
(Takara Bio, Shiga, Japan) in the presence and absence of TER
(0.1–10 μM) and recombinant mouse bone morphogenetic protein
(BMP)-2 (50 ng/ml) (BioLegend, San Diego, CA, United States) for
21 days. Prior to staining, all cells were washed with PBS and fixed
with 4% paraformaldehyde (PFA). Then, the cells were stained with
an Alizarin red staining kit (Cosmo Bio Co., Ltd., Tokyo, Japan) and
an ALP Staining Kit (Fuji Films Co., Tokyo, Japan), following the
manufacturer’s instructions (Aaron et al., 2010).
Statistical Analysis
Experimental results are presented as the mean ± standard deviation
(SD). Multiple comparisons were conducted using one-way analysis
of variance (ANOVA) and Tukey’s test. Statistical analysis software
GraphPad Prism8 (GraphPad Software Inc., San Diego, CA,
United States) was used for each statistical process, and p-values
lower than 0.05 were considered statistically significant.
RESULTS
Synthetic-(+)-Terrein–Suppressed
Ovariectomy-Induced Systemic Bone Loss
OVX models were used to validate the therapeutic value of TER in
suppressing osteoporosis in vivo. TER or PBS (vehicle) was
intraperitoneally injected into OVX mice every 2 days for 8 weeks
before euthanization. Micro CT analyses were performed to
determine the effect of synthetic TER on bone mass (Figure 3A).
Compared to that of the Sham group, BMD, BV/TV, and Tb.N in
the OVX + vehicle group decreased by approximately 16, 80, and
78%, respectively, whereas Tb/Sp increased by 64%. Interestingly,
compared to the OVX group, after treatment with synthetic TER
(30mg/kg), BMD, BV/TV, and Tb.N increased by 7, 239, and 130%,
FIGURE 5 | Synthetic TER did not affect the body weight and serum inflammatory cytokines production. (A) Effect of synthetic TER on body weight. Weight
changes in Sham, OVX, OVX + TER (10–30 mg/kg, two times a week), and OVX + zoledronic acid (ZOL, 0.1 mg/kg, two times a week) groups were observed up to 2, 5,
and 8 weeks after the start of the experiment as relative values (mean ± SD) of the baseline body weight value (100%) at the start of the experiment (n  4–7). The error
bar: SD. (B–E) The amount of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, and M-CSF) in the serum was quantified using ELISA (n  4–7). Columns represent
the mean results of the experiments carried out in, at least, triplicates, and the bars represent the SD (n  4–7, *p < 0.05, ANOVA/Tukey–Kramer test).
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respectively, whereas the relative Tb.Sp decreased by 42%
(Figure 3B, n  6–7, **p < 0.01, *p < 0.05). On the other
hand, an abnormal increase in bone mass was observed in the
ZOL-treated group (Figure 3A). Histomorphometric
assessments (HE staining) validated these results
(Figure 4A). Furthermore, TRAP and IHC staining were
performed for qualitative and quantitative analyses of several
bone parameters that reflect the effect of synthetic TER on
osteoclast formation in vivo (Figures 4B,C). The number of
TRAP-positive osteoclasts and cathepsin-K–positive cells
decreased, together with a dramatic inhibition of osteoclast
formation under treatment with synthetic TER, compared to
the OVX + vehicle group (Figures 4B–D, n  3, **p < 0.01,
*p < 0.05).
Synthetic-(+)-Terrein did Not Affect Body
Weight and Serum Inflammatory Cytokines
Production in Ovariectomized Mice
There were no significant differences in body weight between the
groups treated with/without synthetic TER (30 mg/kg)
(Figure 5A). The serum inflammatory cytokine levels of TNF-
α, IL-1β, IL-6, andM-CSF in the OVXmice did not differ between
the groups treated with/without synthetic TER (30 mg/kg).
However, in the ZOL-treated group, the secretion of
inflammatory cytokines (TNF-α, IL-1β, IL-6, and M-CSF) was
significantly enhanced (Figures 5B–E, n  4–7, *p < 0.05).
Synthetic-(+)-Terrein Inhibited the
Phosphorylation of PKCα/βII and Receptor
Activator of Nuclear Factor-kB
Ligand–Induced Osteoclastogenesis in
Mouse Bone Marrow Macrophages
To elucidate the potential mechanism by which TER inhibits
RANKL-induced osteoclastogenesis, we focused on the PKC
signaling pathway, which is also related to NFATc1 expression
on RANK–RANKL signaling. RANKL stimulation strongly
induced PKCα/βII protein phosphorylation at 30 min. The
treatment with synthetic TER (10 μM) significantly inhibited
RANKL-induced PKCα/βII protein phosphorylation, which is
related to NFATc1 expression (Figures 6A,B, n  3, *p < 0.05).
FIGURE 6 | Synthetic TER suppressed RANKL-induced PKCα/βII phosphorylation and RANKL-induced osteoclastogenesis. (A)Mouse BMMs (1 × 105 cells/well) were
treated with RANKL/M-CSF (100 ng/ml each) in the presence and absence of synthetic TER (10 μM) for 30 min before RANKL stimulation. Total cell extracts were prepared and
subjected to Western blotting using anti–phospho-PKCα/βǁ, total-PKCα, phosphor-PKCδ, and β-actin. (B) The relative density was measured using ImageJ software. Columns
represent the mean results of the experiments carried out in triplicates, and the bars represent the SD (n  3, *p < 0.05, ANOVA/Tukey–Kramer test). (C) Representative
images of a 48-well plate showing the effects of the PKC inhibitor, GF102903X (0.1–10 μM), and synthetic TER (10 μM) on RANKL-induced mBMM-derived osteoclast-like cell
formation stained with tartrate-resistant acid phosphate (TRAP). Numbers next to the images indicate the magnification; scale bar: 200 µm (at a ×200 magnification).
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On the other hand, TER did not suppress PKCδ protein
phosphorylation, which is not related to NFATc1 expression
(Figures 6A,B, n  3). In addition, an osteoclastogenesis assay
was performed to investigate the effect of the PKC inhibitor,
GF109203X, and synthetic TER. Treatment with GF109203X
resulted in the dose-dependent inhibition of RANKL-induced
osteoclast formation, especially in the 10 μMGF109203X-treated
group, as well as GF109203X; synthetic TER (10 μM) inhibited
RANKL-induced osteoclastogenesis in mBMMs completely
(Figure 6C).
Synthetic-(+)-Terrein Suppressed Receptor
Activator of Nuclear Factor-kB
Ligand–Induced mRNA Expression of
Osteoclast Marker Genes in Mouse Bone
Marrow Macrophages
To confirm the effect of TER on the expression of osteoclast
function–related genes, Ocstamp, Dcstamp, Calcr, Atp6v0d2,
Oscar, Trap (Acp5), Cathepsin-K, Itgb3, and c-fos were
determined. Compared to the control group, the expression of
Ocstamp, Dcstamp, Calcr, Atp6v0d2, Oscar, Trap (Acp5),
Cathepsin-K, and Itgb3, but not of c-fos, was significantly
suppressed by synthetic TER (10 μM, Figure 7, n  3, **p < 0.01).
Synthetic-(+)-Terrein did Not Affect
Osteoblast Differentiation in MC3T3-E1
Cells
Whether TER promotes osteoblast differentiation was also
examined using mouse osteoblast-like cells, MC3T3-E1. As
shown in Figure 8, TER treatment did not promote alizarin
red staining and ALP staining activity, while BMP-2 enhanced
both staining and activity (Figures 8A,B, n  3; **p < 0.01). We
also performed IHC staining using an ALP antibody in tissue
sections extracted from OVX mice. There was no statistical
difference in the number of ALP-positive cells in each group
(Figure 8C, n  3).
DISCUSSION
In this study, we demonstrated that synthetic TER is capable of
suppressing RANKL-induced osteoclast differentiation by
inhibiting signaling pathways (PKCα/βII) and downstream
function-related gene expression (OC-stamp, DC-stamp,
calcitonin receptor, and v-type protein ATPase subunit d2).
An OVX mouse model further proved the therapeutic value of
TER in systematic bone loss. The in vitro and in vivo results
FIGURE 7 | Synthetic TER inhibited RANKL-induced mRNA expression of osteoclastogenesis-related factors. Mouse BMMs (1 × 105 cells/well) were incubated in serum-
free medium containing RANKL/M-CSF (100 ng/ml each) in the presence and absence of synthetic TER (10 μM) for 48 h. Cells were lysed, and the total RNA was subjected to
real-time reverse transcription–polymerase chain reaction (RT-PCR) to determine Ocstamp, Dcstamp, Calcr, Atp6v0d2, Oscar, Trap(Acp5), Cathepsin-K, Itgb3, and c-fos gene
expression levels. The columns represent the mean relative intensity of (A)Ocstamp, (B)Dcstamp, (C)Calcr, (D) Atp6v0d2, (E)Oscar, (F) Trap(Acp5), (G)Cathepsin-K, (H)
Itgb3, and (I) c-fos compared to that of β-actin carried out in triplicates, and bars represent the SD (n  3, *p < 0.01, ns: not significant, ANOVA/Tukey–Kramer test).
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indicated that TER probably has therapeutic potential for
osteolytic diseases, including osteoporosis.
Bone homeostasis is maintained by the continuous
progression of bone formation by osteoblasts and bone
resorption by osteoclasts (Matsuo and Irie, 2008; Matsuoka
et al., 2014). Overactivated osteoclasts can induce many
pathological and osteochondrotic diseases, such as
postmenopausal osteoporosis, rheumatoid arthritis, lytic bone
metastases, Paget’s disease, and periodontitis (Zaidi, 2007;
Wackhoure et al., 2009; Kumar et al., 2018). In osteoporosis,
estrogen deficiency leads to elevated levels of RANKL and
inflammatory factors, including IL-6 and TNF-α (Lin et al.,
2019). The overactivation of the RANKL signaling pathway
recruits RANK/TRAF6 association, which in turn promotes
osteoclast reproduction (Chen et al., 2018). Thus, inhibition of
osteoclast formation in the RANKL signaling pathway makes it a
therapeutic target for bone-destroying diseases.
In the present in vivo study, administration of synthetic TER
maintained the bone mineral density, bone mass, and bone girdle
count in OVX mice. Administration of ZOL, one of the BPs,
enhanced the secretion of inflammatory cytokines in the serum,
including TNF- α, IL-1β, IL-6, and M-CSF (Figure 5). On the other
hand, administration of synthetic TER did not enhance the secretion
of inflammatory cytokines in the serum; it had a biosafety impact
compared to ZOL. Therefore, synthetic TER may be a safer
treatment for osteoporosis than the currently used BPs.
FIGURE 8 | Synthetic TER did not affect osteoblast differentiation. Mouse MC3T3-E1 cells (1.0 × 105 cells/well) were treated with ascorbic acid (50 μg/ml) and
hydrocortisone (10 μM)/β-glycerophosphate (10 mM)/bone morphogenetic protein 2 (BMP-2, 100 ng/ml) in the presence or absence of synthetic TER (0.1–10 μM) for
3 weeks. (A) Osteoblast-stained image, alizarin red staining, and ALP staining. (B) Evaluation of calcification and ALP activity (n  3, mean ± SD, *p < 0.05, ANOVA/
Tukey–Kramer test). (C) IHC-stained (anti-ALP antibody) cells.
FIGURE 9 | Schematic representation of the effect of TER on RANKL-
induced osteoclastogenesis via suppressing PKCα/βII phosphorylation.
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NFATc1 plays an indispensable role in RANKL-induced
osteoclast differentiation (Asagiri and Takayanagi, 2007).
NFATc1 functions downstream of NF-κB, MAPKs (ERK1/
2, p38, and MAPK), and Ca2+/calcineurin signaling pathways
(Miyazaki et al., 2000; Takayanagi et al., 2002; Liu et al., 2007;
Negishi-Koga and Takayanagi, 2009), and its activation can
stimulate the expression of bone resorption–related genes,
including Atp6v0d2 (V-ATPase-d2), Itgb3 (integrin 3), Acp5
(TRAP), and Ctsk (cathepsin-K), which are essential for
osteoclast differentiation (Crotti et al., 2008). Consistent
with our findings, TER inhibits RANKL-induced osteoclast
differentiation and bone resorption by inhibiting the
expression of NFATc1 and its downstream bone
resorption–related genes. On the other hand, TER did not
suppress RANKL-induced phosphorylation of NF-κB, ERK,
and p38 in mBMMs (Nakagawa et al., 2020). In this study,
synthetic TER inhibited the RANKL-induced
phosphorylation of PKCα/βII, one of the classical PKC
pathways, and the PKC inhibitor, GF109203X, completely
inhibited RANKL-induced osteoclastogenesis as well as
synthetic TER treatment (Figure 6C). Previous studies
have found that the PKCβ pathway, leading to GSK-3β
inactivation and NFATc1 induction, has a key role in the
RANKL-induced osteoclast differentiation (Shin et al., 2014).
In addition, the PKC inhibitor, GF109203X, suppresses
RANKL-induced calcium oscillations, inhibiting calcium-
dependent NFAT activation in mBMMs (Yao et al., 2015).
It is well known that NFATc1 levels are regulated by
transcriptional control and by the actions of the Ca2+-
dependent phosphatase calcineurin, which stabilizes the
protein and allows its nuclear transportation and
transcriptional activity (Negishi-Koga and Takayanagi,
2009). Thus, the mechanism by which TER inhibits
osteoclast differentiation by suppressing PKCα/βII
phosphorylation, but not NF-κB or MAPKs, was revealed,
which may lead to the elucidation of a new mechanism of
TER for inhibiting osteoclast differentiation via suppressing
Ca2+ oscillation and GSK-3β dynamics that require further
investigation.
For the future pharmacological use of TERs, the efficacy of
synthetic TERs needs to be proven in comparison to existing
osteoporosis drugs, such as BPs. The long half-life of BPs is one of
the problems in osteoporosis treatment for MRONJ. An excessive
increase in bone hardening also conversely increases the risk of
fracture. Synthetic TERs are small molecules and, therefore, may
have a shorter half-life than BPs. They are also expected to
provide a moderate inhibitory effect on bone resorption as a
treatment for patients with early osteoporosis. Therefore, further
studies in an in vivo model are needed to elucidate the systemic
response of TERs.
The present study shows that synthetic TER abrogates
ovariectomy-induced bone loss and RANKL-induced
osteoclastogenesis by suppressing PKCα/βII phosphorylation
(Figure 9). The results provide new insights into the potential
use of TER as an antiresorptive agent in the treatment of
osteolytic bone diseases, including osteoporosis.
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GLOSSARY
TER (+)-terrein
RANKL receptor activator of nuclear factor-kB ligand
OVX ovariectomized
mBMMs mouse bone marrow macrophages
BPs bisphosphonates
MRONJ medicine-induced osteonecrosis of the jaw
TNF-α tumor necrosis factor
IL interleukin
VEGF vascular endothelial growth factor
M-CSF macrophage colony–stimulating factor
JAK-1 Janus-activated kinase
NFATc1 nuclear factor of activated T cell c1





BMD bone mineral density
BV/TV bone volume/trabecular volume
Tb.N trabecular number
Tb.Sp trabecular separation
TRAP tartrate-resistant acid phosphatase
IHC Immunohistochemical
DAB 3,3′-diaminobenzidine
ELISA enzyme-linked immunosorbent assay
FBS fetal bovine serum
SDS sodium dodecyl sulfate
BSA bovine serum albumin
PAGE polyacrylamide gel electrophoresis




PCR polymerase chain reaction
ALP Alkaline phosphatase
BMP bone morphogenetic protein
PFA paraformaldehyde
SD standard deviation
ANOVA analysis of variance
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